Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: An ex vivo study

Hernández, R.; Pajuelo, Jaime Roberto Guerrero; Carvajal, Atiff R.; Padilla, María Cristina Armas; Hernández, María José; Barragan, Oscar; Boada, J

doi:10.1016/0002-8703(91)90878-l

Cited by 16 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treating hypertensive patients with α 1 ‐blockers has been shown to stimulate fibrinolysis and reduce platelet aggregation, while nonselective β‐blockers have opposite effects[110–112]. Calcium channel blockers do not affect fibrinolysis in normotensive volunteers[110], but increase fibrinolytic activity and reduce platelet aggregation in hypertensive patients[110, 113].…”

Section: Other Considerations In the Management Of The Type 2 Diabetimentioning

confidence: 99%

Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus

Marshall¹

1999

Diabetic Medicine

View full text Add to dashboard Cite

Type 2 (noninsulin-dependent) diabetes mellitus (DM) affects about 3% of the UK population. Diabetes often coexists with a cluster of other potent cardiovascular risk factors, including hypertension, dyslipidaemia and increased tendency for thrombosis, and increases the risk of early death from cardiovascular causes by about threefold. Microalbuminuria or proteinuria also may be present, further increasing the risk of cardiovascular mortality. Cardiovascular risk factors must be treated aggressively in patients with Type 2 diabetes and control of blood pressure at 140/85 mm Hg or lower is a priority. The management of hypertension in patients from some ethnic groups demands special consideration because they have a high incidence of diabetes and hypertensive complications. Patients must be urged to adopt appropriate lifestyle changes in the first instance but additional drug treatment for hypertension is usually required. All the major classes of antihypertensive agents lower blood pressure in Type 2 diabetic patients but have different effects on metabolic risk factors in different ways. Low-dose thiazide diuretics, beta-blockers, calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors have been shown to reduce cardiovascular risk. Individually, the effects of low-dose thiazide diuretics and beta-blockers on glucose and lipid metabolism is clinically insignificant, though in combination much larger metabolic effects are seen. ACE inhibitors and calcium channel blockers have no, or small, beneficial effects on glucose and lipid metabolism, while the greater beneficial effects of alpha1-blockers on lipid profiles may render them especially useful in the Type 2 diabetic patient. Long-acting calcium-channel blockers and ACE inhibitors protect renal function and are suitable as first line therapy in patients with microalbuminuria or proteinuria. Until results from the current batch of randomized, placebo-controlled trials comparing different classes of antihypertensive agents are available, the choice of antihypertensive agent is difficult. Addressing overall cardiovascular risk factors, rather than hypertension alone, is essential in the management of the hypertensive Type 2 diabetic patient.

show abstract

Section: Other Considerations In the Management Of The Type 2 Diabetimentioning

confidence: 99%

Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus

Marshall¹

1999

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

“…The same group carried out a further study in a group of 18 hypertensive patients 49 . After 12 weeks of doxazosin treatment, both blood pressure and platelet aggregation were significantly reduced.…”

Section: Epidemiologymentioning

confidence: 99%

Doxazosin: A New Approach to Hypertension and Benign Prostatic Hyperplasia

1996

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY Doxazosin, a selective α1‐adrenoceptor antagonist, is an established first‐line antihypertensive agent that is being introduced for the management of benign prostatic hyperplasia. Hypertension and benign prostatic hyperplasia are linked by the sympathetic nervous system, which has an aetiologic role in both conditions. The α1‐adrenoceptor is a mediator of increased tension, both in vascular and prostatic smooth muscle. Studies have shown that doxazosin, through its balanced action on α1‐adrenoceptor subtypes, reduces blood pressure and improves other risk factors for coronary heart disease, such as lipid profile, insulin sensitivity, left ventricular hypertrophy, platelet aggregation and fibrinolysis. Data are now accumulating to show that doxazosin improves urinary flow rates and symptoms in patients with benign prostatic hyperplasia. These effects have been demonstrated in controlled clinical studies, within weeks, and long term. Since hypertension and benign prostatic hyperplasia are widespread and often undiagnosed in the community, particularly with increasing age, doxazosin may be a particularly appropriate therapy for the considerable number of older men with both conditions.

show abstract

Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

Braschi¹

2019

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: An ex vivo study

Cited by 16 publications

References 22 publications

Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus

Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus

Doxazosin: A New Approach to Hypertension and Benign Prostatic Hyperplasia

Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

Contact Info

Product

Resources

About